The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
Self-citationGerm-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
Self-citationSilencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
Herman, J. G., Latif, F., Weng, Y., Lerman, M. I., Zbar, B., Liu, S., Samid, D., Duan, D. S., Gnarra, J. R., & Linehan, W. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9700 · Cited by 1,529
Self-citationFaster sequential genetic linkage computations.
Cottingham, R. W., Idury, R. M., & Schäffer, A. A. (1993) · Europe PMC (PubMed Central) · Cited by 1,364
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud
Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., & Birchmeier, C. (1995) · Nature · doi:10.1038/376768a0 · Cited by 1,284
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Self-citationMolecular cloning of a new transforming gene from a chemically transformed human cell line
Cooper, C. S., Park, M., Blair, D. G., Tainsky, M. A., Huebner, K., Croce, C. M., & Vande Woude, G. F. (1984) · Nature · doi:10.1038/311029a0 · Cited by 989
Nagata, H., Worobec, A. S., Oh, C. K., Chowdhury, B. A., Tannenbaum, S., Suzuki, Y., & Metcalfe, D. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.23.10560 · Cited by 872
Cited by
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature Reviews Cancer · doi:10.1038/nrc822 · Cited by 6,628
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Met, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
A serine/threonine kinase gene defective in Peutz–Jeghers syndrome
Hemminki, A., Markie, D., Tomlinson, I., Avizienyte, E., Roth, S., Loukola, A., Bignell, G., Warren, W., Aminoff, M., Höglund, P., et al. (1998) · Nature · doi:10.1038/34432 · Cited by 1,656
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,554
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
Tyrosine Kinases as Targets for Cancer Therapy
Krause, D. S., & Van Etten, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044389 · Cited by 1,387
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
The Cancer Genome Atlas Research Network (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505917 · Cited by 1,336
MET signalling: principles and functions in development, organ regeneration and cancer
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3012 · Cited by 1,240
The landscape of kinase fusions in cancer
Stransky, N., Cerami, E., Schalm, S., Kim, J. L., & Lengauer, C. (2014) · Nature Communications · doi:10.1038/ncomms5846 · Cited by 968
Role of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943
Nickerson, M. L., Warren, M. B., Toro, J. R., Matrosova, V., Glenn, G., Turner, M. L., Duray, P., Merino, M., Choyke, P., Pavlovich, C. P., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00104-6 · Cited by 940
Self-citation2004 WHO Classification of the Renal Tumors of the Adults
Lopez-Beltran, A., Scarpelli, M., Montironi, R., & Kirkali, Z. (2006) · European Urology · doi:10.1016/j.eururo.2005.11.035 · Cited by 893
An overview of the c-MET signaling pathway
Organ, S. L., & Tsao, M.-S. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422556 · Cited by 875
Moch, H., Amin, M. B., Berney, D. M., Compérat, E. M., Gill, A. J., Hartmann, A., Menon, S., Raspollini, M. R., Rubin, M. A., Srigley, J. R., et al. (2022) · European Urology · doi:10.1016/j.eururo.2022.06.016 · Cited by 846
Self-citationDrug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
Zou, H. Y., Li, Q., Lee, J. H., Arango, M. E., McDonnell, S. R., Yamazaki, S., Koudriakova, T. B., Alton, G., Cui, J. J., Kung, P.-P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4443 · Cited by 745
Scatter-factor and semaphorin receptors: cell signalling for invasive growth
Trusolino, L., & Comoglio, P. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc779 · Cited by 745
The genetic basis of kidney cancer: a metabolic disease
Linehan, W. M., Srinivasan, R., & Schmidt, L. S. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.47 · Cited by 744
Self-citationInherited susceptibility to uterine leiomyomas and renal cell cancer
Launonen, V., Vierimaa, O., Kiuru, M., Isola, J., Roth, S., Pukkala, E., Sistonen, P., Herva, R., & Aaltonen, L. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633798 · Cited by 669
Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema
Karkkainen, M. J., Ferrell, R. E., Lawrence, E. C., Kimak, M. A., Levinson, K. L., McTigue, M. A., Alitalo, K., & Finegold, D. N. (2000) · Nature Genetics · doi:10.1038/75997 · Cited by 650
Jonasch, E., Gao, J., & Rathmell, W. K. (2014) · BMJ · doi:10.1136/bmj.g4797 · Cited by 636
Toro, J. R., Nickerson, M. L., Wei, M.-H., Warren, M. B., Glenn, G. M., Turner, M. L., Stewart, L., Duray, P., Tourre, O., Sharma, N., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/376435 · Cited by 634
Self-citationThe Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
Linehan, W. M., & Ricketts, C. J. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0211-5 · Cited by 621
Self-citationHuman Cancer Syndromes: Clues to the Origin and Nature of Cancer
Fearon, E. R. (1997) · Science · doi:10.1126/science.278.5340.1043 · Cited by 605
Renal Tumors in the Birt-Hogg-Dubé Syndrome
Pavlovich, C. P., Walther, M. M., Eyler, R. A., Hewitt, S. M., Zbar, B., Linehan, W. M., & Merino, M. J. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200212000-00002 · Cited by 604
Self-citationImproved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors
Nickerson, M. L., Jaeger, E., Shi, Y., Durocher, J. A., Mahurkar, S., Zaridze, D., Matveev, V., Janout, V., Kollarova, H., Bencko, V., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4921 · Cited by 588
Self-citationMa, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M. S., Nallasura, V., Fox, E. A., Hansen, M., Schaefer, E., Naoki, K., Lader, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2650 · Cited by 576
Invasive growth: a MET-driven genetic programme for cancer and stem cells
Boccaccio, C., & Comoglio, P. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1912 · Cited by 538
Shuch, B., Amin, A., Armstrong, A. J., Eble, J. N., Ficarra, V., Lopez-Beltran, A., Martignoni, G., Rini, B. I., & Kutikov, A. (2015) · European Urology · doi:10.1016/j.eururo.2014.04.029 · Cited by 531
Maher, E. R., & Kaelin, W. G. (1997) · Medicine · doi:10.1097/00005792-199711000-00001 · Cited by 528
Clinical, Cellular, and Molecular Aspects of Cancer Invasion
Mareel, M., & Leroy, A. (2003) · Physiological Reviews · doi:10.1152/physrev.00024.2002 · Cited by 524
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer
Eder, J. P., Vande Woude, G. F., Boerner, S. A., & LoRusso, P. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1306 · Cited by 522
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention
Christensen, J. G., Burrows, J., & Salgia, R. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.09.044 · Cited by 513
Malignant melanoma: genetics and therapeutics in the genomic era
Chin, L., Garraway, L. A., & Fisher, D. E. (2006) · Genes & Development · doi:10.1101/gad.1437206 · Cited by 511
c-Met: Structure, functions and potential for therapeutic inhibition
Ma, P. C., Maulik, G., Christensen, J., & Salgia, R. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023768811842 · Cited by 504
Novel mutations of the MET proto-oncogene in papillary renal carcinomas
Schmidt, L., Junker, K., Nakaigawa, N., Kinjerski, T., Weirich, G., Miller, M., Lubensky, I., Neumann, H. P., Brauch, H., Decker, J., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202547 · Cited by 497
Self-citationMotzer, R. J., Bacik, J., Mariani, T., Russo, P., Mazumdar, M., & Reuter, V. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.123 · Cited by 496
Somatic Mutations Lead to an Oncogenic Deletion of Met in Lung Cancer
Kong-Beltran, M., Seshagiri, S., Zha, J., Zhu, W., Bhawe, K., Mendoza, N., Holcomb, T., Pujara, K., Stinson, J., Fu, L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2749 · Cited by 490
Cairns, P. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0176 · Cited by 485
Smolen, G. A., Sordella, R., Muir, B., Mohapatra, G., Barmettler, A., Archibald, H., Kim, W. J., Okimoto, R. A., Bell, D. W., Sgroi, D. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508776103 · Cited by 485
Hepatocyte growth factor twenty years on: Much more than a growth factor
Nakamura, T., Sakai, K., Nakamura, T., & Matsumoto, K. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06549.x · Cited by 470
The Genetic Basis of Cancer of the Kidney
LINEHAN, W. M., WALTHER, M. M., & ZBAR, B. (2003) · Journal of Urology · doi:10.1097/01.ju.0000096060.92397.ed · Cited by 470
Self-citationChoueiri, T. K., Vaishampayan, U., Rosenberg, J. E., Logan, T. F., Harzstark, A. L., Bukowski, R. M., Rini, B. I., Srinivas, S., Stein, M. N., Adams, L. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3383 · Cited by 463
Self-citationTargeting the c-Met Signaling Pathway in Cancer
Peruzzi, B., & Bottaro, D. P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0818 · Cited by 448
Activating mutations for the Met tyrosine kinase receptor in human cancer
Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C. P., Weirich, G., Kishida, T., Zbar, B., & Vande Woude, G. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11445 · Cited by 442
Self-citationA Signaling Adapter Function for α6β4 Integrin in the Control of HGF-Dependent Invasive Growth
Trusolino, L., Bertotti, A., & Comoglio, P. M. (2001) · Cell · doi:10.1016/s0092-8674(01)00567-0 · Cited by 420
Xiao, G.-H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.011532898 · Cited by 417
Met receptor tyrosine kinase: enhanced signaling through adapter proteins
Furge, K. A., Zhang, Y.-W., & Vande Woude, G. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203859 · Cited by 410
Merino, M. J., Torres-Cabala, C., Pinto, P., & Marston Linehan, W. (2007) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31804375b8 · Cited by 409
Maulik, G., Shrikhande, A., Kijima, T., Ma, P. C., Morrison, P. T., & Salgia, R. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00029-6 · Cited by 391
Vanharanta, S., Buchta, M., McWhinney, S. R., Virta, S. K., Peçzkowska, M., Morrison, C. D., Lehtonen, R., Januszewicz, A., Järvinen, H., Juhola, M., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/381054 · Cited by 389
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Drilon, A., Cappuzzo, F., Ou, S.-H. I., & Camidge, D. R. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.014 · Cited by 389
Receptor tyrosine kinase signalling as a target for cancer intervention strategies.
Zwick, E., Bange, J., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080161 · Cited by 384
Targeting RTK Signaling Pathways in Cancer
Regad, T. (2015) · Cancers · doi:10.3390/cancers7030860 · Cited by 380
Schnittger, S., Kohl, T. M., Haferlach, T., Kern, W., Hiddemann, W., Spiekermann, K., & Schoch, C. (2006) · Blood · doi:10.1182/blood-2005-04-1466 · Cited by 380
c-MET as a potential therapeutic target and biomarker in cancer
Sierra, J. R., & Tsao, M.-S. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011422557 · Cited by 365
Use of Antibodies to RCC and CD10 in the Differential Diagnosis of Renal Neoplasms
Avery, A. K., Beckstead, J., Renshaw, A. A., & Corless, C. L. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200002000-00006 · Cited by 360
Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes
Durinck, S., Stawiski, E. W., Pavía-Jiménez, A., Modrusan, Z., Kapur, P., Jaiswal, B. S., Zhang, N., Toffessi-Tcheuyap, V., Nguyen, T. T., Pahuja, K. B., et al. (2015) · Nature Genetics · doi:10.1038/ng.3146 · Cited by 357
Hepatocyte growth factor: Renotropic role and potential therapeutics for renal diseases
Matsumoto, K., & Nakamura, T. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00717.x · Cited by 353
Qian, F., Engst, S., Yamaguchi, K., Yu, P., Won, K.-A., Mock, L., Lou, T., Tan, J., Li, C., Tam, D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4889 · Cited by 350
Germline SDHB Mutations and Familial Renal Cell Carcinoma
Ricketts, C., Woodward, E. R., Killick, P., Morris, M. R., Astuti, D., Latif, F., & Maher, E. R. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn254 · Cited by 342
The Concise Handbook of Family Cancer Syndromes
Lindor, N. M., Greene, M. H., & Program, M. F. C. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.14.1039 · Cited by 339
Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas
Di Renzo, M. F., Olivero, M., Martone, T., Maffe, A., Maggiora, P., De Stefani, A., Valente, G., Giordano, S., Cortesina, G., & Comoglio, P. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203455 · Cited by 332
A novel germ line juxtamembrane Met mutation in human gastric cancer
Lee, J.-H., Han, S.-U., Cho, H., Jennings, B., Gerrard, B., Dean, M., Schmidt, L., Zbar, B., & Vande Woude, G. F. (2000) · Oncogene · doi:10.1038/sj.onc.1203874 · Cited by 329
Self-citationMunshi, N., Jeay, S., Li, Y., Chen, C.-R., France, D. S., Ashwell, M. A., Hill, J., Moussa, M. M., Leggett, D. S., & Li, C. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1173 · Cited by 326
MET-dependent solid tumours — molecular diagnosis and targeted therapy
Guo, R., Luo, J., Chang, J., Rekhtman, N., Arcila, M., & Drilon, A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0377-z · Cited by 323
Lung Cancer Cell Lines Harboring MET Gene Amplification Are Dependent on Met for Growth and Survival
Lutterbach, B., Zeng, Q., Davis, L. J., Hatch, H., Hang, G., Kohl, N. E., Gibbs, J. B., & Pan, B.-S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3495 · Cited by 320
VHL and HIF signalling in renal cell carcinogenesis
Baldewijns, M. M., van Vlodrop, I. J., Vermeulen, P. B., Soetekouw, P. M., van Engeland, M., & de Bruïne, A. P. (2010) · The Journal of Pathology · doi:10.1002/path.2689 · Cited by 316
Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers
Kauffman, E. C., Ricketts, C. J., Rais-Bahrami, S., Yang, Y., Merino, M. J., Bottaro, D. P., Srinivasan, R., & Linehan, W. M. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.162 · Cited by 313
Self-citationHGF/SF‐met signaling in the control of branching morphogenesis and invasion
Zhang, Y., & Vande Woude, G. F. (2003) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10358 · Cited by 307
Tsuda, M., Davis, I. J., Argani, P., Shukla, N., McGill, G. G., Nagai, M., Saito, T., Laé, M., Fisher, D. E., & Ladanyi, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2855 · Cited by 306
The Metabolic Basis of Kidney Cancer
Linehan, W. M., Schmidt, L. S., Crooks, D. R., Wei, D., Srinivasan, R., Lang, M., & Ricketts, C. J. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1354 · Cited by 306
Self-citationMcGarrity, T. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(99)00890-4 · Cited by 303
Expression and mutational analysis of MET in human solid cancers
Ma, P. C., Tretiakova, M. S., MacKinnon, A. C., Ramnath, N., Johnson, C., Dietrich, S., Seiwert, T., Christensen, J. G., Jagadeeswaran, R., Krausz, T., et al. (2008) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20604 · Cited by 300
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
Abounader, R., & Laterra, J. (2005) · Neuro-Oncology · doi:10.1215/s1152851705000050 · Cited by 300
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
Michieli, P., Mazzone, M., Basilico, C., Cavassa, S., Sottile, A., Naldini, L., & Comoglio, P. M. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.032 · Cited by 299
Zhuang, Z., Park, W.-S., Pack, S., Schmidt, L., Vortmeyer, A. O., Pak, E., Pham, T., Weil, R. J., Candidus, S., Lubensky, I. A., et al. (1998) · Nature Genetics · doi:10.1038/1727 · Cited by 291
Self-citationProgress in understanding the molecular pathogenesis of human lung cancer
Sekido, Y., Fong, K. M., & Minna, J. D. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00010-9 · Cited by 290
Maroun, C. R., Naujokas, M. A., Holgado-Madruga, M., Wong, A. J., & Park, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.22.8513-8525.2000 · Cited by 286
Ripperger, T., Bielack, S. S., Borkhardt, A., Brecht, I. B., Burkhardt, B., Calaminus, G., Debatin, K., Deubzer, H., Dirksen, U., Eckert, C., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38142 · Cited by 283
Contemporary Epidemiology of Renal Cell Cancer
Chow, W.-H., & Devesa, S. S. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e3181867628 · Cited by 281
Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J., & Bishop, J. M. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.153.5.1023 · Cited by 281
MET: a promising anticancer therapeutic target
Peters, S., & Adjei, A. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.71 · Cited by 280
The NGS in PPGL (NGSnPPGL) Study Group, Toledo, R. A., Burnichon, N., Cascon, A., Benn, D. E., Bayley, J.-P., Welander, J., Tops, C. M., Firth, H., Dwight, T., et al. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.185 · Cited by 275
Derksen, P. W. B., Keehnen, R. M. J., Evers, L. M., van Oers, M. H. J., Spaargaren, M., & Pals, S. T. (2002) · Blood · doi:10.1182/blood.v99.4.1405 · Cited by 274
Targeting the Hepatocyte Growth Factor–cMET Axis in Cancer Therapy
Blumenschein, G. R., Mills, G. B., & Gonzalez-Angulo, A. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.3774 · Cited by 273
Clifford, S. C., Prowse, A. H., Affara, N. A., Buys, C. H. C. M., & Maher, E. R. (1998) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199807)22:3<200::aid-gcc5>3.0.co;2-# · Cited by 270
Otsuka, T., Takayama, H., Sharp, R., Celli, G. B., LaRochelle, W. J., Bottaro, D. P., Ellmore, N., Vieira, W., Owens, J. W., Anver, M. R., et al. (1998) · PubMed · doi:10.5281/zenodo.894795 · Cited by 268
Choosing the right cell line for renal cell cancer research
Brodaczewska, K. K., Szczylik, C., Fiedorowicz, M., Porta, C., & Czarnecka, A. M. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0565-8 · Cited by 267
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Armes, J. E., Egan, A. J. M., Southey, M. C., Dite, G. S., McCredie, M. R. E., Giles, G. G., Hopper, J. L., & Venter, D. J. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981201)83:11<2335::aid-cncr13>3.0.co;2-n · Cited by 259
Lubensky, I. A., Schmidt, L., Zhuang, Z., Weirich, G., Pack, S., Zambrano, N., Walther, M. M., Choyke, P., Linehan, W. M., & Zbar, B. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65147-4 · Cited by 256
Self-citationMolecular genetics and clinical features of Birt–Hogg–Dubé syndrome
Schmidt, L. S., & Linehan, W. M. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.206 · Cited by 255
Self-citationVillalobos, P., & Wistuba, I. I. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.006 · Cited by 254
The MET receptor tyrosine kinase in invasion and metastasis
Benvenuti, S., & Comoglio, P. M. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21183 · Cited by 253
Receptor tyrosine kinases as targets for anticancer drugs
Zwick, E., Bange, J., & Ullrich, A. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02217-1 · Cited by 252
HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence
Fu, J., Su, X., Li, Z., Deng, L., Liu, X., Feng, X., & Peng, J. (2021) · Oncogene · doi:10.1038/s41388-021-01863-w · Cited by 235
Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint
Kleiblova, P., Shaltiel, I. A., Benada, J., Ševčík, J., Pecháčková, S., Pohlreich, P., Voest, E. E., Dundr, P., Bartek, J., Kleibl, Z., et al. (2013) · Journal of Cell Biology · doi:10.1083/jcb.201210031 · Cited by 170
Metadata
- Authors
- Schmidt, L., Duh, F.-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C. J. M., Walther, M. M., Tsui, L.-C., Geil, L., Orcutt, M. L., Stackhouse, T., Lipan, J., Slife, L., Brauch, H., Decker, J., Niehans, G., Hughson, M. D., Moch, H., Storkel, S., Lerman, M. I., Linehan, W. M., & Zbar, B.
- Venue
- Nature Genetics
- Published
- 1997-05
- Volume
- 16
- Issue
- 1
- Pages
- 68-73
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2019573100
- Cited by
- 1,524
- References
- 30
- FWCI
- 65.20
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.